Abstract CT016: Feasibility and efficacy of perioperative nivolumab with or without relatlimab for patients with potentially resectable hepatocellular carcinoma

作者：Hui Li, Sarah M. Shin, Anne M. Noonan, Chester Kao, Christopher Shubert, Ewa Kulikowicz, Dimitrios N. Sidiropoulos, Jennifer N. Durham, Mari Nakazawa, Waqar Arif, Benjamin Philosophe, William R. Burns, Jin He, Kelly Lafaro, Richard A. Burkhart, Marco Dal Molin, Brad Wilt, Robert A. Anders, Tania Nevers, Elizabeth M. Jaffee, Daniel A. Laheru, H Wang, Marina Baretti, Won Jin Ho, Mark Yarchoan · 发表于：Cancer Research · 年份：2026 · DOI：10.1158/1538-7445.am2026-ct016 · 被引用次数：1 · 研究领域：Cancer Immunotherapy and Biomarkers、Hepatocellular Carcinoma Treatment and Prognosis、Cancer, Stress, Anesthesia, and Immune Response

Abstract Background: Most patients with hepatocellular carcinoma (HCC) experience recurrence after curative-intent resection, highlighting the need for effective perioperative therapies. Neoadjuvant immunotherapy has shown feasibility and pathological changes in clinical trials of early-stage HCC. Here, we evaluate the feasibility of perioperative nivolumab monotherapy and nivolumab plus relatlimab, as dual PD-1 and LAG-3 blockade may synergistically restore T-cell function. Methods: From 2021 to 2025, we conducted an open label, noncomparative, randomized phase II clinical trial (NCT04658147) in patients with potentially resectable HCC with high-risk features (large tumor size, multinodular disease, macrovascular involvement). Patients were randomized to receive 2 doses over 8 weeks of nivolumab (Arm A) or nivolumab with relatlimab (Arm B) prior to surgical resection. Eligible patients continued systemic therapy following resection for up to 10 months. The primary endpoint was feasibility, defined as the proportion of patients who experienced an unacceptable treatment-related adverse which prevented surgery. Secondary endpoints included proportion of complete/major pathologic response, objective response rate (ORR), disease-free survival (DFS), and overall survival (OS). Results: Thirty patients were randomized and received at least one dose of systemic therapy (n=15 per study arm). In both study arms, the trial met its primary endpoint as no patients experienced treatment-r...